NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen announced that its Board of Directors has approved a stock buyback plan on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Thursday, January, 30th. The biotechnology company reported $8.34 EPS for the quarter, topping the consensus estimate of $8.02 by $0.32. The biotechnology company earned $3.67 billion during the quarter, compared to analyst estimates of $3.51 billion. Biogen had a net margin of 40.96% and a return on equity of 46.51%. Biogen's revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.99 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Biogen.

Biogen updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

34 brokerages have issued 1-year price objectives for Biogen's stock. Their forecasts range from $230.00 to $410.00. On average, they anticipate Biogen's stock price to reach $322.85 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Biogen.

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 19 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

Press coverage about BIIB stock has trended very negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Biogen.

Biogen saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 3,110,000 shares, a decrease of 13.6% from the January 30th total of 3,600,000 shares. Based on an average daily trading volume, of 1,820,000 shares, the short-interest ratio is presently 1.7 days. Approximately 1.8% of the shares of the company are sold short. View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Intel (INTC).

Biogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.56%), Renaissance Technologies LLC (2.63%), Geode Capital Management LLC (1.90%), AQR Capital Management LLC (1.51%), Bank of New York Mellon Corp (1.22%) and Capital World Investors (1.05%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Alliancebernstein L.P., Jackson Square Partners LLC, AQR Capital Management LLC, Macquarie Group Ltd., FMR LLC, State Street Corp and Assenagon Asset Management S.A.. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Bank of New York Mellon Corp, Fred Alger Management LLC, First Trust Advisors LP, Samlyn Capital LLC and Marshall Wace North America L.P.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $308.39.

Biogen has a market capitalization of $53.68 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.View Additional Information About Biogen.

The official website for Biogen is http://www.biogen.com/.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]